WO2003070751A3 - Partial peptide mimetics and methods - Google Patents
Partial peptide mimetics and methods Download PDFInfo
- Publication number
- WO2003070751A3 WO2003070751A3 PCT/US2003/005106 US0305106W WO03070751A3 WO 2003070751 A3 WO2003070751 A3 WO 2003070751A3 US 0305106 W US0305106 W US 0305106W WO 03070751 A3 WO03070751 A3 WO 03070751A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- partial peptide
- peptide mimetics
- methods
- homolog
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4747—Apoptosis related proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003211163A AU2003211163A1 (en) | 2002-02-20 | 2003-02-20 | Partial peptide mimetics and methods |
EP03742842A EP1572719A4 (en) | 2002-02-20 | 2003-02-20 | Partial peptide mimetics and methods |
CA002476427A CA2476427A1 (en) | 2002-02-20 | 2003-02-20 | Partial peptide mimetics and methods |
JP2003569658A JP2005536453A (en) | 2002-02-20 | 2003-02-20 | Partial peptide mimetics and methods |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35927202P | 2002-02-20 | 2002-02-20 | |
US60/359,272 | 2002-02-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003070751A2 WO2003070751A2 (en) | 2003-08-28 |
WO2003070751A3 true WO2003070751A3 (en) | 2007-04-05 |
Family
ID=27757772
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/005106 WO2003070751A2 (en) | 2002-02-20 | 2003-02-20 | Partial peptide mimetics and methods |
Country Status (6)
Country | Link |
---|---|
US (2) | US7056514B2 (en) |
EP (1) | EP1572719A4 (en) |
JP (1) | JP2005536453A (en) |
AU (1) | AU2003211163A1 (en) |
CA (1) | CA2476427A1 (en) |
WO (1) | WO2003070751A2 (en) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2000511892A (en) * | 1996-05-24 | 2000-09-12 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Synthesis of soluble beta-sheet forming peptide |
JP2005536453A (en) * | 2002-02-20 | 2005-12-02 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Partial peptide mimetics and methods |
BR0314619A (en) * | 2002-09-18 | 2005-08-02 | Univ Montreal Ct Hospitalier Chum | Ghrh's analogs |
CA2541856A1 (en) * | 2003-10-17 | 2005-05-12 | Regents Of The University Of Minnesota | Modified polypeptides with therapeutic activity and methods of use |
US20060053172A1 (en) * | 2004-09-03 | 2006-03-09 | Biowisdom Limited | System and method for creating, editing, and using multi-relational ontologies |
CA2867023A1 (en) | 2004-10-04 | 2006-04-20 | Kevin H. Mayo | Calixarene-based peptide conformation mimetics, methods of use, and methods of making |
EP2131861A2 (en) * | 2007-03-01 | 2009-12-16 | Mallinckrodt Inc. | Integrated photoactive small molecules and uses thereof |
CN101626786A (en) * | 2007-03-01 | 2010-01-13 | 马林克罗特公司 | Integrated photoactive peptides and uses thereof |
WO2009018405A1 (en) * | 2007-07-31 | 2009-02-05 | Mallinckrodt Inc. | Integrated photoactive agents and uses thereof |
JP2021529163A (en) | 2018-06-29 | 2021-10-28 | グリコス バイオメディカル オーワイ | Conjugate |
US20230038373A1 (en) | 2019-12-18 | 2023-02-09 | Glykos Biomedical Oy | Stabile conjugate |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955577A (en) * | 1996-06-27 | 1999-09-21 | Regents Of The University Of Minnesota | Method for synthesizing a water-soluble β-sheet forming peptide |
US6486125B1 (en) * | 1996-05-24 | 2002-11-26 | Regents Of The University Of Minnesota | Synthesis of soluble β-sheet forming peptides |
US7056514B2 (en) * | 2002-02-20 | 2006-06-06 | Regents Of The University Of Minnesota | Partial peptide mimetics and methods |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5198541A (en) | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
EP0375724B1 (en) | 1987-08-11 | 1995-05-31 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5334584A (en) | 1989-02-14 | 1994-08-02 | Incyte Pharamaceuticals, Inc. | Recombinant, non-glycosylated bpi protein and uses thereof |
US5089274A (en) | 1989-02-14 | 1992-02-18 | Incyte Pharmaceuticals, Inc. | Use of bactericidal/permeability increasing protein or biologically active analogs thereof to treat endotoxin-related disorders |
US5234912A (en) | 1989-02-14 | 1993-08-10 | Incyte Pharmaceuticals, Inc. | Pharmaceutical compositions comprising recombinant BPI proteins and a lipid carrier and uses thereof |
US5171739A (en) | 1989-02-14 | 1992-12-15 | Incyte Pharmaceuticals, Inc. | Treatment of endotoxin-associated shock and preventation thereof using a BPI protein |
US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
US5595887A (en) | 1990-07-16 | 1997-01-21 | Bionebraska, Inc. | Purification directed cloning of peptides using carbonic anhydrase as the affinity binding segment |
JPH06502993A (en) | 1990-11-28 | 1994-04-07 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | Structural proteins from artificial genes |
EP0563222B1 (en) | 1990-12-03 | 1998-02-25 | New York University | Biologically active bactericidal/permeability-increasing protein fragments |
US5190873A (en) | 1991-06-21 | 1993-03-02 | California Institute Of Biological Research | Hybrid tryptophan aporepressor containing ligand binding sites |
US5643570A (en) | 1992-05-19 | 1997-07-01 | Xoma Corporation | BPI-immunoglobulin fusion proteins |
EP0675127A1 (en) | 1992-12-28 | 1995-10-04 | Nippon Shinyaku Company, Limited | Quinolinecarboxylic acid derivative and process for producing the same |
CA2155005C (en) | 1993-02-02 | 1999-04-06 | Weldon Courtney Mcgregor | Pharmaceutical compositions containing bactericidal permeability increasing protein and a surfactant |
US5420019A (en) | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5348942A (en) | 1993-03-12 | 1994-09-20 | Xoma Corporation | Therapeutic uses of bactericidal/permeability increasing protein products |
NZ263344A (en) | 1993-03-12 | 1997-08-22 | Xoma Corp | Human bactericidal/permeability increasing (bpi) protein functional domain peptides and their use |
CA2161971A1 (en) | 1993-04-30 | 1994-11-10 | Randal W. Scott | Recombinant bpi-based and lbp-based proteins, nucleic acid molecules encoding same, methods of producing same, and uses thereof |
US5731415A (en) | 1993-06-17 | 1998-03-24 | Xoma Corporation | Lipopolysaccharide binding protein derivatives |
AU7217094A (en) | 1993-07-02 | 1995-01-24 | Incyte Pharmaceuticals, Inc. | Glycosylated and non-glycosylated bactericidal/permeability increasing proteins, and methods for producing same |
WO1995002414A1 (en) | 1993-07-14 | 1995-01-26 | Xoma Corporation | Method for potentiating bpi protein product bactericidal activity by administration of lbp protein products |
US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
US5786324A (en) | 1994-03-24 | 1998-07-28 | Regents Of The University Of Minnesota | Synthetic peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5830860A (en) | 1994-03-24 | 1998-11-03 | Regents Of The University Of Minnesota | Peptides with bactericidal activity and endotoxin neutralizing activity for gram negative bacteria and methods for their use |
US5837682A (en) | 1996-03-08 | 1998-11-17 | The Children's Medical Center Corporation | Angiostatin fragments and method of use |
US5639725A (en) | 1994-04-26 | 1997-06-17 | Children's Hospital Medical Center Corp. | Angiostatin protein |
GB9506806D0 (en) | 1995-04-01 | 1995-05-24 | Univ Leeds | Improvements relating to polymers |
EP0831872A4 (en) | 1995-05-26 | 2002-10-28 | Torrey Pines Inst | Polypeptide compounds that form beta sheets |
US5854205A (en) | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
EP1252181B1 (en) | 2000-01-20 | 2006-01-18 | Regents Of The University Of Minnesota | Peptides with antibacterial activity |
CA2541856A1 (en) | 2003-10-17 | 2005-05-12 | Regents Of The University Of Minnesota | Modified polypeptides with therapeutic activity and methods of use |
ITPD20040171A1 (en) | 2004-06-29 | 2004-09-29 | Maus Spa | DEVICE FOR THE LOCKING OF PARTS SUBJECT TO MECHANICAL PROCESSING AND MACHINE TOOL INCLUDING THIS DEVICE |
CA2867023A1 (en) | 2004-10-04 | 2006-04-20 | Kevin H. Mayo | Calixarene-based peptide conformation mimetics, methods of use, and methods of making |
US20070010438A1 (en) * | 2005-07-08 | 2007-01-11 | Mayo Kevin H | Tumor treatment using beta-sheet peptides and radiotherapy |
-
2003
- 2003-02-20 JP JP2003569658A patent/JP2005536453A/en active Pending
- 2003-02-20 WO PCT/US2003/005106 patent/WO2003070751A2/en active Application Filing
- 2003-02-20 EP EP03742842A patent/EP1572719A4/en not_active Withdrawn
- 2003-02-20 AU AU2003211163A patent/AU2003211163A1/en not_active Abandoned
- 2003-02-20 CA CA002476427A patent/CA2476427A1/en not_active Abandoned
- 2003-02-20 US US10/371,406 patent/US7056514B2/en not_active Expired - Lifetime
-
2006
- 2006-02-02 US US11/346,504 patent/US7339023B2/en not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6486125B1 (en) * | 1996-05-24 | 2002-11-26 | Regents Of The University Of Minnesota | Synthesis of soluble β-sheet forming peptides |
US5955577A (en) * | 1996-06-27 | 1999-09-21 | Regents Of The University Of Minnesota | Method for synthesizing a water-soluble β-sheet forming peptide |
US7056514B2 (en) * | 2002-02-20 | 2006-06-06 | Regents Of The University Of Minnesota | Partial peptide mimetics and methods |
Non-Patent Citations (1)
Title |
---|
See also references of EP1572719A4 * |
Also Published As
Publication number | Publication date |
---|---|
US7056514B2 (en) | 2006-06-06 |
EP1572719A2 (en) | 2005-09-14 |
WO2003070751A2 (en) | 2003-08-28 |
AU2003211163A1 (en) | 2003-09-09 |
US20040053828A1 (en) | 2004-03-18 |
US7339023B2 (en) | 2008-03-04 |
CA2476427A1 (en) | 2003-08-28 |
EP1572719A4 (en) | 2007-11-14 |
AU2003211163A8 (en) | 2003-09-09 |
JP2005536453A (en) | 2005-12-02 |
US20060128629A1 (en) | 2006-06-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004043382A3 (en) | Enhanced variants of erythropoietin and methods of use | |
EP1803733A3 (en) | Use of a polypeptide comprising the extracellular domains of IL-20RA and IL-20RB for the treatment of inflammation | |
WO2003012105A3 (en) | Vegf isoform | |
EP1308459A3 (en) | Full-length cDNA sequences | |
EP1085089A3 (en) | Human cyclic nucleotide phosphodiesterase | |
EP1440981A3 (en) | Full-length human cdna | |
WO2003070751A3 (en) | Partial peptide mimetics and methods | |
EP2314604A3 (en) | Nucleic acids coding for adhesion factors of group B streptococcus, adhesion factors of group B streptococcus and further uses thereof | |
WO2002072616A3 (en) | Transfection complexes | |
EP1092727A3 (en) | G-protein receptor | |
WO2003048205A3 (en) | Novel proteins with il-6 inhibiting activity | |
WO2002046415A3 (en) | Polynucleotide and polypeptide sequences of putative transporters and ion channells | |
WO2002101052A3 (en) | Salutaridinol 7-o-acetyltransferase and derivatives thereof | |
WO2001046260A3 (en) | Novel immunoglobulin superfamily members apex-1, apex-2 and apex-3 and uses thereof | |
WO2003097791A3 (en) | Polynucleotide sequences encoding alkaline a-galactosidases and methods of using same | |
DE60109412D1 (en) | Therapeutische peptide | |
GB9416536D0 (en) | Orphan receptor | |
WO2001053347A3 (en) | Nphs2 gene involved in the cortico-resistant neprhotic syndrome, protein encoded by said gene and diagnostic and therapeutic uses | |
WO2001087932A3 (en) | Seven transmembrane proteins and polynucleotides encoding the same | |
EP2143730A3 (en) | Modified peptides and their use for the treatment of autoimmune diseases | |
GB2356864B (en) | Novel polypeptide | |
WO2001092468A3 (en) | Novel compositions for the expression of the human peptide histidine transporter 1 and methods of use thereof | |
EP1096008A3 (en) | Human G protein-coupled receptor, PFI-014 | |
WO2003054009A3 (en) | Apoptotically active peptides | |
WO2007073845A8 (en) | Polypeptide having esterase activity and recombinant esterase and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2476427 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003569658 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003742842 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003742842 Country of ref document: EP |